Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CMV-Vac
- Development stage
- Preclinical
- Lead developer
- ViferaXS
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
CMV-Vac is a preclinical T cell activating vaccine being developed by ViferaXS for the prevention or treatment of Cytomegalovirus (CMV) infection. The vaccine is engineered using T cell activator technology to target specific CMV antigens, with the goal of eliciting a robust and specific T cell immune response. By stimulating cellular immunity, CMV-Vac aims to provide protection against CMV, which is a significant cause of morbidity in immunocompromised individuals, such as transplant recipients, and can lead to severe congenital complications when transmitted during pregnancy.
- Other names
- cytomegalovirus vaccineViferaXS CMV vaccine
Beyond the preview
Go deeper on CMV-Vac.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CMV-Vac.